Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform. Alcyone Therapeutics’ lead programs target the treatment of Rett syndrome and spinal muscular atrophy with respiratory distress type 1 (SMARD1). 

Biotechnology

Alcyone Therapeutics

Pj Anand

Natalia Podporina

Todd Washburn

Stephen Oesterle

Rich Upton

Kathrin Meyer

John L. McGuire

Greg Smith

David Johnson

Burt Raymond

Andrew East

Ravi Mehrotra

The Research and Development team at Alcyone Therapeutics focuses on innovating and advancing gene therapy solutions for severe neurological conditions. This team, composed of scientists and engineers, collaborates to develop and optimize the company's proprietary CNS delivery technology, conduct preclinical research, and advance clinical programs targeting Rett syndrome and SMARD1. Their efforts are critical in transforming scientific breakthroughs into effective therapies that enhance patient outcomes in the central nervous system.

Research and Development

Clinical and Regulatory Affairs

Leadership Team

Research and Development

About

Team members

Other teams at Alcyone Therapeutics

Clinical and Regulatory Affairs

Leadership Team